On April 13, 2026, Allogene Therapeutics announced interim results from its ALPHA3 trial, revealing that 58.3% of patients treated with cema-cel achieved minimal residual disease (MRD) negativity compared to 16.7% in the observation group, indicating a significant difference of 41.6%. The ongoing study aims to improve outcomes for high-risk large B-cell lymphoma patients.